Meeting NewsVideo

VIDEO: Bayer executive highlights ASCO data in breast cancer, urothelial carcinoma, glioblastoma

CHICAGO — Scott Z. Fields, MD, senior vice president and head of pharmaceutical development for oncology at Bayer, spoke with HemOnc Today at ASCO Annual Meeting about key company data presented at the meeting.

Fields discussed copanlisib (Aliqopa, Bayer), a PI3 kinase inhibitor approved for treatment of patients with pretreated follicular lymphoma.

A phase 1 study presented at ASCO explored the combination of copanlisib with trastuzumab (Herceptin, Genentech) for pretreated recurrent or metastatic HER-2-positive breast cancer. The regimen appeared feasible and will move into a phase 2 study.

A phase 1 dose escalation study assessed the FGFR inhibitor rogaratinib (Bayer) for patients with advanced urothelial carcinoma prescreened for tumor FGFR mRNA expression. That research will advance to a phase 2/phase 3 study that will compare rogaratinib with chemotherapy, Fields said.

Fields also highlighted data related to the multikinase inhibitor regorafenib (Stivarga, Bayer) for treatment of glioblastoma, and provided an update on larotrectinib (LOXO-101; Bayer, Loxo Oncology), an oral and selective drug intended to treatment patients with cancers that harbor abnormalities in the tropomyosin receptor kinases. The FDA granted priority review to an application that seeks approval of larotrectinib for treatment of certain solid tumors.

CHICAGO — Scott Z. Fields, MD, senior vice president and head of pharmaceutical development for oncology at Bayer, spoke with HemOnc Today at ASCO Annual Meeting about key company data presented at the meeting.

Fields discussed copanlisib (Aliqopa, Bayer), a PI3 kinase inhibitor approved for treatment of patients with pretreated follicular lymphoma.

A phase 1 study presented at ASCO explored the combination of copanlisib with trastuzumab (Herceptin, Genentech) for pretreated recurrent or metastatic HER-2-positive breast cancer. The regimen appeared feasible and will move into a phase 2 study.

A phase 1 dose escalation study assessed the FGFR inhibitor rogaratinib (Bayer) for patients with advanced urothelial carcinoma prescreened for tumor FGFR mRNA expression. That research will advance to a phase 2/phase 3 study that will compare rogaratinib with chemotherapy, Fields said.

Fields also highlighted data related to the multikinase inhibitor regorafenib (Stivarga, Bayer) for treatment of glioblastoma, and provided an update on larotrectinib (LOXO-101; Bayer, Loxo Oncology), an oral and selective drug intended to treatment patients with cancers that harbor abnormalities in the tropomyosin receptor kinases. The FDA granted priority review to an application that seeks approval of larotrectinib for treatment of certain solid tumors.

    See more from ASCO Annual Meeting